In a report released on January 30, Conor McNamara from RBC Capital maintained a Buy rating on QuidelOrtho (QDEL – Research Report), with a price target of $125.00. The company’s shares closed yesterday at $88.51. McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Illumina, and Bio-Rad Laboratories. According to TipRanks, McNamara has an average return of 4.2% and a 66.67% success rate on recommended stocks.  QuidelOrtho has an analyst consensus of Strong Buy, with a price target consensus of $130.40. See the top stocks recommended by analysts >> The company has a one-year high of $120.61  and a one-year low of $66.88. Currently, QuidelOrtho has an average volume of 627.7K.
		  TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.  Read More on QDEL: Indices Commodities Currencies Stocks